Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGuilarte Clavero, Mar
dc.contributor.authorBaeza, María Luisa
dc.contributor.authorCabañas, Rosario
dc.contributor.authorHernández, María Dolores
dc.contributor.authorIbañez, Ethel
dc.contributor.authorSala Cunill, Anna
dc.date.accessioned2022-06-16T07:25:31Z
dc.date.available2022-06-16T07:25:31Z
dc.date.issued2021-12-29
dc.identifier.citationGuilarte M, Sala-Cunill A, Baeza ML, Cabañas R, Hernández MD, Ibañez E, et al. Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain. Allergy, Asthma Clin Immunol. 2021 Dec 29;17:137.
dc.identifier.issn1710-1492
dc.identifier.urihttps://hdl.handle.net/11351/7700
dc.descriptionBradicinina; Angioedema hereditari; Icatibant
dc.description.sponsorshipThe Icatibant Outcome Survey is funded and supported by Shire International GmbH, a Takeda company, Zurich, Switzerland. Under direction of the authors, Alpa Parmar, PhD, CMPP, Latoya M. Mitchell, PhD, CMPP, and Sophia Shumyatsky, PharmD, CMPP, employees of Excel Medical Affairs, provided writing assistance for this manuscript. Editorial assistance in formatting, proofreading, and copyediting also was provided by Excel Medical Affairs. Takeda Development Center Americas, Inc. provided funding to Excel Medical Affairs, provided funding to Excel Medical Affairs for support in editing this manuscript. The interpretation of the data was made by the authors independently.
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofseriesAllergy, Asthma & Clinical Immunology;17
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMalalties congènites - Tractament
dc.subjectInflamació
dc.subjectProteïna C - Deficiència
dc.subject.meshAngioedemas, Hereditary
dc.subject.mesh/drug therapy
dc.subject.meshSurveys and Questionnaires
dc.subject.meshTime-to-Treatment
dc.titleHereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s13223-021-00641-3
dc.subject.decsangioedemas hereditarios
dc.subject.decs/farmacoterapia
dc.subject.decsencuestas y cuestionarios
dc.subject.decstiempo hasta el tratamiento
dc.relation.publishversionhttps://doi.org/10.1186/s13223-021-00641-3
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Guilarte M, Sala-Cunill A] Secció d’Al•lèrgia, Servei de Medicina, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Research Network on Allergy (National Allergy Network ARADyAL: Asma, Reacciones Adversas y Alérgicas), Instituto de Salud Carlos III, Madrid, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Baeza ML] Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Biomedical Research Network on Rare Diseases, CIBERER-U761, Gregorio Marañón Health Research Institute, Madrid, Spain. [Cabañas R] Allergy Department, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research (IdiPaz), Madrid, Spain. Biomedical Research Network on Rare Diseases, CIBERER-U754, Madrid, Spain. [Hernández MD, Ibañez E] Allergy Department, IIS-Hospital Universitari I Politècnic La Fe, Valencia, Spain
dc.identifier.pmid34965883
dc.identifier.wos000736714300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple